Stories about therapy

Subscribe to topic

Subscribe to therapy

30.09.2019 – 10:40
QUANTIC NANOTECH
First Digital Health Osteoarthritis Wearable Glove System Starts Pre-launch Pilot Trial Series & Medical Tests
Madrid (ots/PRNewswire) - QUANTIC NANOTECH, a product division of Spanish DEMAC S.A. group who presented the first home wearable osteoarthritis treatment glove system "QNANO GLOVE" during the last CES 2019 Edition in Las Vegas, announced today the opening of free treatment sign-up registration for a new medical ...
more
19.03.2019 – 23:47
Merck KGaA
Merck and Pfizer Announce Discontinuation of Phase III JAVELIN Ovarian PARP 100 Trial in Previously Untreated Advanced Ovarian Cancer
Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for US, Canada and UK-based media Merck and Pfizer Inc. (NYSE: PFE) today announced the discontinuation of the ongoing Phase III JAVELIN Ovarian PARP 100 study evaluating the efficacy and safety of avelumab in combination with chemotherapy followed by ...
more
03.01.2019 – 11:43
ATAI Life Sciences
ATAI Life Sciences acquires majority stake in Perception Neuroscience to develop arketamine therapy for neuropsychiatric diseases
Munich and New York (ots) - ATAI Life Sciences AG has acquired a majority stake in New York based Perception Neuroscience, a biopharmaceutical company focused on developing innovative therapies in neuropsychiatry. Perception was founded by Jonathan Sporn, MD, and Jay Kranzler, MD, PhD, both of whom have held ...
more
13.12.2018 – 16:06
OD-OS GmbH
APVRS 2018: Intuitive Iridotomy Treatment with the Navilas® 577s Retina Laser Released by OD-OS
more
26.11.2018 – 10:01
Kyowa Kirin International PLC
Kyowa Kirin Announces POTELIGEO® Receives Marketing Authorisation in Europe for the Treatment of Mycosis Fungoides and Sézary Syndrome
Tokyo (ots/PRNewswire) - POTELIGEO will be the first biologic agent targeting CCR4 to be available for patients in Europe. Kyowa Hakko Kirin Co., Ltd., (Kyowa Kirin) announces today that it has received a European Commission decision granting a marketing authorisation to POTELIGEO® (Generic name: mogamulizumab), a ...
more
25.10.2018 – 13:34
Helmholtz Zentrum München
Two-pronged approach - Novel combined therapy tackles excess fatty tissue
A new combined therapy for obesity and diabetes has been shown to suppress the appetite and at the same time increase energy expenditure. Scientists from the Helmholtz Zentrum München and the Technical University of Munich (TUM), partner institutions of the German Center for Diabetes Research (DZD), have reported their findings in 'Nature Communications'. "Obesity is ...
more
18.10.2018 – 09:32
Technische Universität München
Test predicts outcome of hay fever therapies
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 22731 - email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/detail/article/35000/ NEWS RELEASE Test predicts outcome of hay fever therapies Allergy researchers look into molecular processes in hyposensitization to pollen Allergen-specific immunotherapy can make everyday life ...
more
17.10.2018 – 13:31
Accuray
Accuray Showcases Radiation Therapy Innovations Designed to Improve What's Possible for Patients at ASTRO 2018
Sunnyvale, California (ots/PRNewswire) - Building on its heritage of patient-first innovation, at this year's ASTRO (American Society for Radiation Oncology) Annual Meeting, Accuray Incorporated (NASDAQ: ARAY) will showcase radiation therapy solutions designed to enable clinicians to deliver truly personalized ...
more
15.10.2018 – 13:06
Sysmex Inostics GmbH
Sysmex Inostics' OncoBEAM(TM) liquid biopsy technology demonstrates utility for clinical management of melanoma patients undergoing treatment with targeted therapy and immune checkpoint inhibitors
Hamburg, Germany (ots) - Sysmex Inostics, a pioneer in blood-based circulating tumor DNA (ctDNA) analysis and molecular diagnostics for oncology, is pleased to announce publication of a study in the Journal of Molecular Oncology highlighting the important clinical value of blood-based ctDNA mutation testing to ...
more
08.08.2018 – 18:40
Kyowa Kirin International PLC
Kyowa Kirin Announces FDA Approval of Poteligeo® (mogamulizumab-kpkc) for the Treatment of Mycosis Fungoides and Sézary Syndrome
Tokyo (ots/PRNewswire) - - Poteligeo has been approved for the treatment of the two most common types of Cutaneous T-cell lymphoma (CTCL) in previously treated patients based on data showing improved progression-free survival (PFS) and overall response rate (ORR) when compared to vorinostat. - FDA approval was based ...
more
29.06.2018 – 01:02
Astellas Pharma Europe Limited
Results From Pivotal Phase 3 PROSPER Trial of XTANDI[TM] (enzalutamide) in Men With Non-Metastatic Castration-Resistant Prostate Cancer Published in New England Journal of Medicine
Tokyo (ots/PRNewswire) - Results show enzalutamide plus androgen deprivation therapy significantly reduced the risk of developing metastases or death by 71 percent compared to placebo plus androgen deprivation therapy[i] FOR EMEA MEDICAL MEDIA ONLY - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji ...
more
24.02.2012 – 08:55
Astellas Pharma Europe Limited
New Class of Treatment for Overactive Bladder Demonstrates Efficacy and Tolerability Across Three Separate Studies
Paris (ots/PRNewswire) - ASTELLAS PHARMA EUROPE Ltd., European subsidiary of Tokyo-based Astellas Pharma Inc. today announced results from three separate clinical trials that further support the efficacy and tolerability of mirabegron. Mirabegron, a beta3 adrenoceptor agonist, is the first in a new class of ...
more

1